Teva Submits Fremanezumab for FDA ApprovalLast Updated:
Key milestone reached for Teva to advance global fremanezumab program for the preventive treatment of migraine. Fremanezumab aims to address unmet need in migraine community, a disease with currently limited preventive therapeutic options.
A second CGRP monoclonal antibody is now awaiting FDA approval.
Source: Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA